Brief: Theranexus: FDA Issues Favorable Opinion On Preclinical Development Plan Submitted By Theranexus, BBDF
19/11/2020 06:44
Nov 19 (Reuters) - Theranexus SA ALTHX.PA :
* FDA ISSUES A FAVORABLE OPINION ON PRECLINICAL DEVELOPMENT
PLAN
SUBMITTED BY THERANEXUS AND BBDF
* APPROVING THERANEXUS' PROPOSALS TO CONTINUE PRECLINICAL
DEVELOPMENT OF BBDF-101 PREVIOUSLY INITIATED BY COMPANY
Source text for Eikon: ID:nACT66199
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease